Trevi Therapeutics (TRVI) Free Cash Flow (2018 - 2026)

Trevi Therapeutics' Free Cash Flow history runs 9 years deep, the most recent figure standing at -$16.8 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 24.59% year-over-year to -$16.8 million in Q1 2026; TTM through Mar 2026 was -$45.4 million, a 10.04% decrease from a year earlier, with the FY2025 full-year figure at -$42.1 million, down 9.95% from the prior year.
• Free Cash Flow fell to -$16.8 million in Q1 2026 per TRVI's latest filing, from -$7.6 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$6.2 million in Q2 2022 and bottomed at -$16.8 million in Q1 2026.
• The 5-year median for Free Cash Flow is -$8.7 million (2024), against an average of -$9.3 million.
• Across the five-year window, Free Cash Flow climbed 21.8% in 2022 and sank 60.54% in 2023, its largest moves.
• Year by year, Free Cash Flow stood at -$6.4 million in 2022, then climbed by 1.02% to -$6.4 million in 2023, then tumbled by 49.77% to -$9.6 million in 2024, then rose by 20.15% to -$7.6 million in 2025, then plunged by 120.04% to -$16.8 million in 2026.
• Per Business Quant, the three latest TRVI Free Cash Flow figures stand at -$16.8 million (Q1 2026), -$7.6 million (Q4 2025), and -$10.9 million (Q3 2025).